Sector News

Edwards Lifesciences to buy Israel's Valtech for up to $690 million

November 28, 2016
Life sciences

Edwards Lifesciences Corp on Monday said it has agreed to buy Israel’s Valtech Cardio for $340 million in stock and cash, with the potential for an additional $350 million in pre-specified milestone-driven payments over the next 10 years.

Valtech is a private company that developed a system for transcatheter repair of the heart’s mitral and tricuspid valves.

Eyal Lifschitz, chief executive of the Peregrine Ventures fund that invested in and helped start Valtech, said Valtech has so far raised about $100 million.

Other investors include OXO Capital Valve Ventures and NGN Capital.

Prior to the deal’s closing, which is expected in early 2017, Valtech will spin off its early-stage transseptal mitral valve replacement technology program.

Edwards also has an option to buy that program, which Lifschitz said could bring the total paid to close to $1 billion.

Separately, Edwards’ board of directors said it authorized a new share repurchase program to acquire up to an additional $1 billion of the company’s outstanding common shares.

By Ari Rabinovitch

Source: Reuters

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach